Actinium develops Antibody Radiation Conjugates ('ARCs') and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and re... Actinium develops Antibody Radiation Conjugates ('ARCs') and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia ('r/r AML'), which Actinium plans to advance with a potential strategic partner in the U.S. following completion of FDA interactions. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute ('NCI') under the Cooperative Research and Development Agreement ('CRADA') for development of Actimab-A in AML and other myeloid malignancies. 더 보기
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. PR Newswire NEW YORK, Aug. 5, 2024 FDA determined that the Phase 3 SIERRA trial is not adequate...
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications PR...
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University PR...
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US PR Newswire NEW YORK, July 25, 2024 Presentation to highlight positive outcomes of Iomab-B led bone...
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid...
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial PR Newswire NEW YORK, June...
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting PR Newswire NEW...
Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.09 | -4.61538461538 | 1.95 | 2.28 | 1.68 | 483667 | 1.95233551 | CS |
4 | -5.71 | -75.429326288 | 7.57 | 8.64 | 1.33 | 842477 | 3.18164222 | CS |
12 | -4.71 | -71.6894977169 | 6.57 | 10.24 | 1.33 | 582659 | 4.97772373 | CS |
26 | -5.14 | -73.4285714286 | 7 | 10.24 | 1.33 | 389054 | 5.15243839 | CS |
52 | -4.21 | -69.3574958814 | 6.07 | 15.12 | 1.33 | 356221 | 7.25794521 | CS |
156 | 1.625 | 691.489361702 | 0.235 | 15.12 | 0.1506 | 1781840 | 1.54261008 | CS |
260 | 0 | 0 | 0 | 2.01 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관